SYMBOL:

    Up to 100 tickers separated by a space
Site Map FAQ Contact us Home Personalize
Company
Industry
Earnings
US Markets
Most Active
Portfolio
Tools
ETFs
Ratings
BIOCRYST PHARMACEUTICALS
(NQNM:BCRX Last Sale: 3.93 +0)
Fundamentals Charts Tech Analysis Industry Earnings
Company Profile   Details

Company Web Site
NQNM: (BCRX : $3.93)
$606,231 million Market Cap at Market Close, July 1, 2022
Employs 80.
Biomedics SubIndustry up .00% / Health Industry up .00% Today
2190 Parkway Lake Drive Research Report Earnings Snapshot - Last 11/06/18
Birmingham, AL 35244 Fact Sheet
Phone: (205) 444-4600 Financial Statements
Fax: (205) 444-4640 Peer Comparison
Annual Reports

Charles E. Bugg, Founder, Non Ex. Chmn., Jon Stonehouse, CEO/Pres., Stuart Grant, CFO
Announced positive results on two late-stage studies of flu therapy Peramivir with Japanese partner Shionogi July 17, 2009. Also has research underway on the cancer drug Fodosine and BCX-4208, a treatment for autoimmune diseases. Biopharmaceutical company using structure-based drug design to develop small molecule pharmaceutical products for the treatment of T-cell proliferation disorders, infectious diseases and certain cardiovascular disorders. Received "orphan drug" status for an anti-cancer compound August 23, 2004. Founded in 1986.
Historical Charts    Technical Analysis
No Historical Data available for BCRX

Type of Stock Symbol Last Sale Last Close Net +/- % +/- Low High Volume 52wk Low 52wk High Shares(M)
Common BCRX $3.93 $3.93 0 .0 $3.38 $3.93 9,217,921 $3.38 $3.93 154,257,247
Capitalization
Earnings Summary ()
*** No Earnings Available***
-10121
Common Stock $606,230,981

A381
Google



QUICK NAVIGATION SITE SEARCH   Enter Keyword:
   
Home    Subscribe    Browser Help    Subscriber Services    B-to-B    Banks    Brokerage    Telco    Site Map    Legal    Contact/Email
Copyright © 1996 - 2024 Stock Smart with all rights reserved
Feed is currently being brought back up
Provided by Nanex